Xencor (NASDAQ:XNCR) Stock Passes Above 50 Day Moving Average - Time to Sell?

Key Points

• Xencor crossed above its 50-day moving average of $12.19, trading as high as $13.56 and last at $13.10 (200-day MA $13.67).
• Wall Street consensus is a Moderate Buy with a $24.38 average price target, based on six Buys, two Holds and one Sell and mixed recent analyst revisions.
• The company reported quarterly EPS of ($0.09), beating estimates of ($0.64), but revenue of $28.24M missed expectations and fell 46.6% year-over-year; Xencor remains unprofitable and insiders sold 44,020 shares last quarter.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $12.19 and traded as high as $13.56. Xencor shares last traded at $13.10, with a volume of 1,115,833 shares.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on XNCR shares. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $13.00 price target (down from $18.00) on shares of Xencor in a report on Tuesday, March 24th. Wall Street Zen upgraded Xencor from a "sell" rating to a "hold" rating in a report on Saturday, April 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a report on Friday, March 27th. Finally, Barclays increased their price target on Xencor from $26.00 to $27.00 and gave the stock an "overweight" rating in a report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and a consensus price target of $24.38.

Xencor Stock Up 0.9%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The company has a market cap of $960.75 million, a price-to-earnings ratio of -10.56 and a beta of 0.99. The business has a 50-day simple moving average of $12.19 and a 200-day simple moving average of $13.67.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.55. The company had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.Xencor's revenue for the quarter was down 46.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.62) EPS. On average, equities analysts anticipate that Xencor, Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 6,606 shares of the stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $11.02, for a total value of $72,798.12. Following the sale, the chief executive officer owned 546,316 shares of the company's stock, valued at $6,020,402.32. This trade represents a 1.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Celia Eckert sold 3,244 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $36,495.00. Following the sale, the senior vice president directly owned 78,685 shares in the company, valued at $885,206.25. This trade represents a 3.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 44,020 shares of company stock valued at $499,817 in the last quarter. Corporate insiders own 5.23% of the company's stock.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently made changes to their positions in XNCR. AQR Capital Management LLC acquired a new stake in shares of Xencor during the 1st quarter worth about $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock worth $471,000 after buying an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock worth $7,732,000 after buying an additional 344,088 shares during the last quarter. Creative Planning grew its stake in Xencor by 25.3% during the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company's stock worth $143,000 after buying an additional 3,661 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Xencor by 170.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company's stock worth $2,594,000 after buying an additional 208,182 shares during the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.